Article info

Download PDFPDF
Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching

Authors

  1. Correspondence to Dr Fabrizio Cantini, Department of Rheumatology, Azienda USL Toscana Centro, Hospital of Prato, Prato 59100, Italy; fbrzcantini{at}gmail.com
View Full Text

Citation

Cantini F, Benucci M
Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching

Publication history

  • Received November 13, 2018
  • Accepted November 17, 2018
  • First published November 28, 2018.
Online issue publication 
January 27, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.